Gyroscope Therapeutics, spun out of Cambridge and Syncona, has merged with Orbit Biomedical to form a fully-integrated retinal gene therapy developer.
Gyroscope Therapeutics, a UK-based retinal gene therapy developer partly based on University of Cambridge research, has merged with US-based medical device manufacturer Orbit Biomedical.
The merged business will operate under the Gyroscope name and act as a fully-integrated gene therapy company with clinical, manufacturing and delivery capabilities. Gyroscope claimed in its announcement the merger would make it the first such end-to-end gene therapy provider.
Founded in 2016, Gyroscope is working on retinal gene therapies for dry age-related macular degeneration, a condition that leads to vision loss.
The spinout commercialises research undertaken in the lab of Sir Peter Lachmann, emeritus Sheila Joan Smith professor of immunology at University of Cambridge’s Department of Veterinary Medicine and the founding president of the UK’s Academy of Medical Sciences.
Gyroscope also exploits studies on potential patient populations undertaken by David Kavanagh, professor of complement therapeutics at Newcastle University, and Andrew Lotery,…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
